{"groups":[{"description":"Patients randomized to Cedinarib reference arm during the recruitment period (09/04/2018-06/17/2019). Patients receive Cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nCediranib: Given PO\n\nCediranib Maleate: Given PO\n\nComputed Tomography: Undergo CT scan\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA","id":"FG000","title":"Arm I (Cediranib maleate_Reference Group 1)"},{"description":"Patients receive olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nComputed Tomography: Undergo CT scan\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA\n\nOlaparib: Given PO","id":"FG001","title":"Arm II (Olaparib)"},{"description":"Patients receive olaparib PO BID and cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nCediranib: Given PO\n\nCediranib Maleate: Given PO\n\nComputed Tomography: Undergo CT scan\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA\n\nOlaparib: Given PO","id":"FG002","title":"Arm III (Cediranib Maleate, Olaparib)"},{"description":"Patients receive olaparib PO BID on days 1-28 and capivasertib PO BID on days 1-4 each week. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nCapivasertib: Given PO\n\nComputed Tomography: Undergo CT scan\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA\n\nOlaparib: Given PO","id":"FG003","title":"Arm IV (Olaparib, Capivasertib)"},{"description":"Patients receive olaparib PO BID on days 1-28 and durvalumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nComputed Tomography: Undergo CT scan\n\nDurvalumab: Given IV\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA\n\nOlaparib: Given PO","id":"FG004","title":"Arm V (Olaparib, Durvalumab)"},{"description":"Patients receive cediranib maleate PO QD on days 1-5 each week and durvalumab IV on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nCediranib Maleate: Given PO\n\nComputed Tomography: Undergo CT scan\n\nDurvalumab: Given IV\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA","id":"FG005","title":"Arm VI (Cediranib Maleate, Durvalumab)"},{"description":"Patients randomized to Cedinarib reference arm during the recruitment period (08/16/2021-06/28/2023).\n\nPatients receive cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nCediranib: Given PO\n\nCediranib Maleate: Given PO\n\nComputed Tomography: Undergo CT scan\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUG","id":"FG006","title":"Arm VII (Cediranib maleate_Reference Group 2)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"40"},{"groupId":"FG002","numSubjects":"40"},{"groupId":"FG003","numSubjects":"42"},{"groupId":"FG004","numSubjects":"42"},{"groupId":"FG005","numSubjects":"43"},{"groupId":"FG006","numSubjects":"41"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"40"},{"groupId":"FG002","numSubjects":"40"},{"groupId":"FG003","numSubjects":"42"},{"groupId":"FG004","numSubjects":"42"},{"groupId":"FG005","numSubjects":"43"},{"groupId":"FG006","numSubjects":"41"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Trial first activated on 09/04/2018 with reporting groups 1-3. It closed to accrual for reporting groups 1-3 on 06/17/2019. It reopened to accrual for reporting groups 4-7 on 08/16/2021. It closed to accrual for reporting groups 4-7 on 06/28/2023."}